5th International HIV/Viral Hepatitis Co-Infection Meeting

Viral hepatitis elimination in Latin America and globally: How close are we?

Saturday - Sunday, 20-21 July 2019
Mexico City, Mexico
Implementation and access to medicines

Giten Khwairakpam
TREAT Asia/amfAR
Bangkok, Thailand
Outline

• Background: Viral hepatitis and HIV
• Implementation of hepatitis C programs
• Access to DAAs
  – Regulatory status
  – Pricing
• Conclusions
Viral hepatitis and HIV

- **New infections**
  - 1.1 million by HBV in 2017
  - 1.75 million by HCV in 2015
  - 1.8 million by HIV in 2017

- **Mortality**
  - 1.4 million died of viral hepatitis in 2016
  - 1.22 million died from HBV and HCV in 2016
  - 940,000 died of HIV in 2017

- **Awareness**
  - 27 million knew about their HBV status in 2016
  - 13.1 million knew about their HCV status in 2017
  - 75% knew about their HIV status in 2017

- **Treatment**
  - 4.5 million treated for HBV in 2016
  - 5 million treated for HCV by 2017
  - 79% treated for HIV in 2017

*Global Hepatitis Report 2017, WHO and Global Health Observatory Data
Progress report on HIV, Viral hepatitis and STI 2019, WHO*
Implementation of viral hepatitis programs

As of February 2019, 124 countries had national hepatitis action plans compared to 17 in 2012.

- National plans on viral hepatitis
  - 15 countries in the Americas
  - 17 countries in the Western Pacific
  - 3 countries in South East Asia

- 12 countries on track to eliminate hepatitis C by 2030*
  - Australia, Egypt, France, Georgia, Iceland, Italy, Japan, Mongolia, Netherlands, Spain, Switzerland, United Kingdom

- 84% of high-income countries not on track to eliminate hepatitis C by 2030#

* Center for Disease Analysis, June 2018
# Razavi H, Global timing of hepatitis C virus elimination, ILC 2019

World Health Organization, April 2019
Regulatory status and access to DAAs

- **Sovaldi®** FDA approval: Dec 2013
- Generic licenses signed: Sep 2014
- **Harvoni®** FDA approval: Oct 2014
- **Daklinza®** FDA approval: July 2015
- Licenses through MPP: Nov 2015

Sources: Gilead, July 2019; and Indian generic manufacturers as on July 2019; Daklinza status: Progress report on Access to hepatitis C treatment, WHO, March 2018
Price reductions in Indian generic DAAs for private purchase up to June 2019

USD per bottle

- Sofosbuvir
- Ledipasvir/sofosbuvir
- Daclatasvir
- Velpatasvir/sofosbuvir
Pricing variations of generic DAAs

<table>
<thead>
<tr>
<th>Country</th>
<th>Sofosbuvir</th>
<th>Ledipasvir/sofosbuvir</th>
<th>Daclatasvir</th>
<th>Velpatasvir</th>
</tr>
</thead>
<tbody>
<tr>
<td>India</td>
<td>$10</td>
<td>$19</td>
<td>$31</td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>$91</td>
<td>$109</td>
<td>$136</td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>$272</td>
<td>$414</td>
<td>$125</td>
<td></td>
</tr>
<tr>
<td>Cambodia</td>
<td>$200</td>
<td>$40</td>
<td>$40</td>
<td></td>
</tr>
<tr>
<td>Vietnam</td>
<td>$300</td>
<td>$330</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myanmar</td>
<td>$40</td>
<td>$95</td>
<td>$55</td>
<td></td>
</tr>
<tr>
<td>Ukraine</td>
<td>$20</td>
<td>$30</td>
<td>$6</td>
<td></td>
</tr>
</tbody>
</table>

Approx USD per bottle
Conclusions

• New infections and deaths from viral hepatitis continue
• More people know about their infection status and treatment options
• Countries beginning to recognize the human and financial burdens of viral hepatitis and taking action
• National drug regulatory approvals for DAAs are increasing while prices continue to drop
  – Reductions are inconsistent and governments need more effective procurement mechanisms to access lower pricing